Successful treatment of multidrug-resistant Candida auris ventriculitis with Intraventricular Caspofungin: first report from Türkiye
The Journal of Infection in Developing Countries · 2026-10-31 · 20 (10) · 1566-1570
DOI: 10.3855/jidc.22209 ↗Abstract
Introduction: Candida auris is an emerging multidrug-resistant fungus with limited therapeutic options. Central nervous system (CNS) infections are exceptionally rare and difficult to treat due to poor antifungal penetration. Case presentation: This case report presents a 55-year-old woman with hydrocephalus and an external ventricular drain who developed Candida auris ventriculitis on day 48 of her intensive care unit stay. Based on CLSI (Clinical and Laboratory Standards Institute) interpretive criteria, the isolate demonstrated resistance to amphotericin B (MIC 4 µg/mL) and caspofungin (MIC 8 µg/mL), while remaining susceptible to anidulafungin (MIC 0.5 µg/mL). Results: Intravenous anidulafungin and intraventricular (IVT) caspofungin (10 mg daily) achieved cerebrospinal fluid sterilization within 72 hours, despite the high in-vitro MIC. Conclusions: This first report from Türkiye demonstrates the potential efficacy of IVT caspofungin in multidrug-resistant Candida auris ventriculitis, emphasizing the importance of pharmacokinetic studies to refine CNS dosing strategies and susceptibility breakpoints.
EUVIMED